ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CGTX Cognition Therapeutics Inc

2.00
-0.07 (-3.38%)
Mar 01 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 216,667
Bid Price 1.98
Ask Price 2.13
News -
Day High 2.11

Low
0.9001

52 Week Range

High
3.49

Day Low 1.98
Company Name Stock Ticker Symbol Market Type
Cognition Therapeutics Inc CGTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -3.38% 2.00 19:03:31
Open Price Low Price High Price Close Price Prev Close
2.10 1.98 2.11 2.00 2.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,338 216,667 $ 2.05 $ 443,380 - 0.9001 - 3.49
Last Trade Time Type Quantity Stock Price Currency
19:25:42 87 $ 2.01 USD

Cognition Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
60.53M 30.42M - 0 -21.4M -0.70 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cognition Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CGTX Message Board. Create One! See More Posts on CGTX Message Board See More Message Board Posts

Historical CGTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.992.281.902.02172,0560.010.50%
1 Month2.302.46031.902.03264,208-0.30-13.04%
3 Months1.452.791.442.02249,9740.5537.93%
6 Months1.592.790.90011.75167,4290.4125.79%
1 Year1.693.490.90011.90135,6840.3118.34%
3 Years12.1513.800.90013.17163,522-10.15-83.54%
5 Years12.1513.800.90013.17163,522-10.15-83.54%

Cognition Therapeutics Description

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Your Recent History

Delayed Upgrade Clock